^
Association details:
| Biomarker: | miR-200-c expression |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | erlotinib (EGFR inhibitor) + mirdametinib (PD-0325901) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Subtype Specific MEK – PI3 Kinase Feedback as a Therapeutic Target in Pancreatic Adenocarcinoma
Excerpt:
We found that all five members of the microRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141 and miR-429) and in addition, miR-155, -139-5p, and 135b were markedly upregulated in sensitive, but almost not expressed in resistant cell lines (Fig. 5).
DOI:
10.1158/1535-7163.MCT-13-0104
